Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA

Kedudukan dalam Saham #10263
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Harga Saham
$3.48
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$820.97M
Perubahan (1 hari)
8.32%
Perubahan (1 tahun)
-8.38%
Negara
FR
Perdagangan Inventiva S.A. (IVA)

Kategori

Healthcare
Bilangan saham terbitan bagi Inventiva S.A. (IVA)
Bilangan saham terbitan setakat October 2026: 0
Menurut laporan kewangan terkini dan harga saham Inventiva S.A., bilangan saham terbitan semasa ialah 0. Pada akhir October 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Inventiva S.A. (IVA) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL